Back to top

earnings-estimates-revisions: Archive

Zacks Equity Research

Commercial Metals (CMC) Earnings Expected to Grow: Should You Buy?

Commercial Metals (CMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CMCNegative Net Change

Zacks Equity Research

TD SYNNEX (SNX) Reports Next Week: Wall Street Expects Earnings Growth

TD SYNNEX (SNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SNXPositive Net Change

Zacks Equity Research

McCormick (MKC) Reports Next Week: What Awaits?

McCormick (MKC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MKCPositive Net Change

Zacks Equity Research

Darden Restaurants (DRI) Reports Next Week: Wall Street Expects Earnings Growth

Darden Restaurants (DRI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DRIPositive Net Change

Zacks Equity Research

Analysts Estimate American Outdoor Brands, Inc. (AOUT) to Report a Decline in Earnings: What to Look Out for

American Outdoor Brands (AOUT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AOUTPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

IMMXNegative Net Change

Zacks Equity Research

Wall Street Analysts See a 39.86% Upside in Mama's Creations, Inc. (MAMA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Mama's Creations, Inc. (MAMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MAMAPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 30.99% Upside in Franco-Nevada (FNV): Here's What You Should Know

The mean of analysts' price targets for Franco-Nevada (FNV) points to a 31% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FNVNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe Roper Technologies (ROP) Could Rally 36.61%: Here's is How to Trade

The mean of analysts' price targets for Roper Technologies (ROP) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ROPPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SGRYPositive Net Change